Breast Cancer

Study : Moderate exercise delays time to breast cancer recurrence

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: People with breast cancer who are interested in using exercise to reduce risk of recurrence

For premenopausal women with early-stage breast cancer, physical activity may increase the time before cancer returns and spreads. In this study, people with hormone receptor-negative (HR-negative) breast cancer benefited from moderate exercise—more than those with hormone receptor-positive (HR-positive) breast cancer. This study found that outcomes improved when weekly exercise time was between 90 minutes and 5 hours.  (Posted 11/14/24)

Study : Impact of breast cancer and BRCA mutations on fertility preservation

Relevance: Medium

Strength of Science: Medium

Research Timeline: Post Approval

Most relevant for: People considering fertility preservation.

Timely family planning discussions are important for people diagnosed with breast cancer as well as those who have an inherited a BRCA1 or BRCA2 mutation. This study looked at the number of mature eggs recovered when ovaries were stimulated for fertility preservation or preimplantation genetic testing among three groups and found that the number of eggs collected was similar. (Posted 10/31/24)

Study : Use of cannabis for cancer symptom management

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People with cancer interested in using cannabis to help manage symptoms.

Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)

Este artículo está disponible en español.

Study : Combining two anti-HER2 drugs improves outcomes more effectively than one

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with Her2-positive metastatic breast cancer

Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)

Este artículo está disponible en español.

Update : News from the FDA: Updates on breast cancer treatment

Relevance: Medium

Research Timeline: Post Approval

Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.

The FDA updates the risks of using BioZorb Markers, approves a new imaging drug and shares the Oncology Podcast Series. (Posted 8/16/24)

Este artículo está disponible en español.

Topic : Acupressure for cancer symptom relief

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People diagnosed with cancer

Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)

Este artículo está disponible en español.

Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with advanced HER2-positive cancer

The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)

Este artículo está disponible en español.

Topic : Experts call for early palliative care for cancer patients

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: Cancer patients

People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)

Este artículo está disponible en español.

Study : Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with a BRCA1 or BRCA2 mutation who are considering breast MRI screening

An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)

Este artículo está disponible en español.

Update : Targeted therapy for early-stage HER2-positive breast cancer continues to show benefit

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People with early-stage HER2-postive breast cancer

People with early-stage HER2-positive breast cancer benefit from targeted therapy. This update includes new data on survival and the length of time without cancer returning. (Posted 6/20/24)

Este artículo está disponible en español.